Fig. 3From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in SpainScatterplot of incremental cost and incremental QALYs. Abbreviations: CE, cost-effectiveness WTP, willingness to pay; QALY, quality-adjusted life yearBack to article page